Daunorubicin Hydrochloride
Brand Names: Daunorubicin Hydrochloride Generic
Methodology & AI Transparency ⓘ
Daunorubicin Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: Daunorubicin hydrochloride in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
- 2 Real-world patient consensus: Real-world cohort score of 76% across 19 de-identified Daunorubicin Hydrochloride entries.
- 3 Typical cash cost range: Dispensing cost comparison spans $122.31 mail/discount cash up to $299.66 uninsured retail (federal NADAC $2.8100).
- 4 Top reported side effects / signs: Most commonly reported Daunorubicin Hydrochloride tolerability events: nausea (11.3%), diarrhea (8.6%), abdominal discomfort (4.1%).
Ask our AI Specialists anything about Daunorubicin Hydrochloride
Daunorubicin Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: Daunorubicin hydrochloride in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
CLINICAL PHARMACOLOGY Mechanism of Action Daunorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action. Daunorubicin forms complexes with DNA by intercalation between base pairs. It inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. Single strand and double strand DNA breaks result. Daunorubicin hydrochloride may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA.
Following administration (5 mg/mL Injection, Solution), Daunorubicin Hydrochloride achieves Complete (~100%) parenteral systemic delivery for Daunorubicin Hydrochloride (5 mg/mL Injection, Solution) bioavailability and rapid intravascular/parenteral onset within 15–45 minutes after daunorubicin hydrochloride administration onset, governed by a Elimination kinetics span 8 to 17 hours per Daunorubicin Hydrochloride clinical pharmacology terminal half-life through systemic clearance of daunorubicin hydrochloride integrates hepatic phase ii conjugation with renal filtration.
Before initiating Daunorubicin Hydrochloride at 5 mg/mL Injection, Solution, clinical safety checklists rule out contraindications daunorubicin hydrochloride is contraindicated in patients who have shown a hypersensitivity to it.; history of severe allergic sensitivity to daunorubicin hydrochloride active moiety or formulation vehicle. Logged tolerability patterns center on nausea (11.3% of reports), diarrhea (8.6% of reports), headache (6.7% of reports).
Verify medication reconciliation lists so Daunorubicin Hydrochloride is not inadvertently duplicated with another anthracycline topoisomerase inhibitor.
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Daunorubicin Hydrochloride dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS Daunorubicin hydrochloride is contraindicated in patients who have shown a hypersensitivity to it.
- History of severe allergic sensitivity to Daunorubicin Hydrochloride active moiety or formulation vehicle
Logged Side-Effect Incidence (19 Reports)
Daunorubicin Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Daunorubicin Hydrochloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Glasdegib plus intensive or non-intensive chemotherapy for untreated acute: What a 404-Participant Study Found The addition of glasdegib to either cytarabine and daunorubicin or azacitidine did not significantly improve overall survival and the primary efficacy endpoint for the BRIGHT AML 1019 phase 3 trial was not met. Leukemia • 2023-10-15 • Phase III Randomized Trial | N = 404 | 93/100 | PMID 37604981 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet Early mortality was lower, and hospitalization length of stay per patient-year was shorter with CPX-351 versus 7 + 3 within the adverse-risk and intermediate-risk subgroups. Journal of hematology & oncology • 2022-10-26 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36289532 ↗ |
| Can This Approach Help? Inside the Latest Research on Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs Conclusion: MCMs are well suited to modeling long-term survival in acute myeloid leukemia patients. Future oncology (London, England) • 2021-08-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33858190 ↗ |
| Can This Approach Help? Inside the Latest Research on Older adults with newly diagnosed high-risk/secondary AML who achieved full These results suggest deeper remissions may be achieved with CPX-351, leading to improved OS. Blood advances • 2021-03-23 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33724305 ↗ |
Daunorubicin Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.8100/unit (~$84.30/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $299.66 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 19 Anonymous DotMD Community Micro-Logs | $122.31 / mo | View logs ↓ |
Daunorubicin Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Daunorubicin Hydrochloride RxNorm Concept ID | 309650 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.8100 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $299.66 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $122.31 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 76.00% Worth It (19 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Daunorubicin Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Cross-verified Daunorubicin Hydrochloride (anthracycline topoisomerase inhibitor) monograph synthesizing RxNorm 309650, openFDA FAERS signals, and $122.31–$299.66 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Daunorubicin Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.